Enzyme immunoassay for the quantitative determination of free Infliximab (Remsima®) in serum and plasma
Remsima®,the world first biosimilar mAb (approved in 2013 by EMA). The Agencys Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade®. The Matriks Biotek Shikari® Infliximab-Remsima® ELISA has been especially developed for the quantitative analysis of free infliximab in serum and plasma samples.
|Required Volume (µl)||10|
|Total Time (min)||70|
|Detection Limit (ng/mL)||100|
|Spike Recovery (%)||Between 85-115|
|Shelf Life (year)||1|